• Sorafenib (BAY-43-9006): Systems Biology and Host-Directed I

  2026-06-02

  Explore how Sorafenib (BAY-43-9006) advances cancer biology research and host-targeted antiviral strategies through dynamic transcriptomics. This article delivers a deeper, systems-level perspective on Sorafenib’s unique utility and mechanistic insights.

• (S)-Mephenytoin as a Benchmark CYP2C19 Substrate in Organoid

  2026-06-01

  (S)-Mephenytoin is redefining CYP2C19 substrate assays by enabling highly predictive, human-relevant drug metabolism workflows using hiPSC-derived intestinal organoids. This article delivers actionable protocol enhancements, troubleshooting guidance, and comparative analysis for translational pharmacokinetic studies leveraging APExBIO’s validated compound.

• Anti-ROR1 Antibody (Zilovertamab): Precision Tools for Model

  2026-06-01

  Explore how Anti-ROR1 Antibody (Zilovertamab) enables precision inhibition of Wnt5a-induced ROR1 signaling for advanced cancer and liver injury research. This article delivers new insights into experimental modeling, bridging mechanistic depth with practical protocol innovation.

• Bedaquiline: Precision Targeting in Tuberculosis and Oncolog

  2026-05-31

  Explore the unique diarylquinoline antibiotic Bedaquiline and its dual role in multi-drug resistant tuberculosis treatment and cancer stem cell inhibition. This article delivers a scientifically rigorous, application-focused analysis distinct from existing content.

• miR-18a/ALOXE3 Axis in Ferroptosis and Migration of Glioblas

  2026-05-30

  The reference study elucidates the tumor-promoting role of miR-18a in glioblastoma (GBM) through direct suppression of ALOXE3, affecting ferroptosis and cell migration. These findings reveal an actionable molecular axis with potential for targeted GBM research and interventions.

• SGC-CBP30: Precision Bromodomain Inhibition for Epigenetics

  2026-05-29

  SGC-CBP30 empowers advanced epigenetics and cancer biology research by selectively inhibiting CREBBP/EP300 bromodomains, enabling targeted dissection of super-enhancer regulation and transcriptional coactivator pathways. This article details practical workflows, troubleshooting strategies, and application-driven insights anchored in the latest lung adenocarcinoma research.

• Nonconventional Agonist–Antagonist Interplay at the GLP-1R

  2026-05-29

  Chepurny et al. (2019) reveal that glucagon acts as a nonconventional agonist at the GLP-1 receptor, challenging established views of receptor selectivity. High-throughput FRET cAMP assays demonstrate complex cross-reactivity between glucagon, GLP-1, and receptor antagonists, informing metabolic regulation and type 2 diabetes research.

• Tigecycline (SKU A5226): Data-Driven Solutions for Resistant

  2026-05-28

  This authoritative guide addresses real-world laboratory challenges in cell viability, proliferation, and cytotoxicity assays, focusing on Tigecycline (SKU A5226) as a robust, data-backed solution. Drawing on peer-reviewed research and practical workflow considerations, the article equips biomedical researchers and lab technicians with scenario-driven insights for optimizing experimental reproducibility and tackling multidrug-resistant bacteria.

• Neticonazole Hydrochloride: Imidazole Antifungal in Oncology

  2026-05-28

  Neticonazole Hydrochloride distinguishes itself as a dual-action imidazole antifungal with validated applications in both mycology and colorectal cancer research. This article delivers actionable protocols, troubleshooting strategies, and expert insights for leveraging Neticonazole Hydrochloride across experimental workflows, including exosome pathway modulation and apoptosis induction.

• QNZ (EVP4593): Advanced NF-κB Pathway Modulation in Research

  2026-05-27

  QNZ (EVP4593) is redefining NF-κB pathway modulation with nanomolar potency and proven translational value in both inflammation and neurodegenerative disease models. This article delivers actionable workflows, troubleshooting strategies, and insight into leveraging QNZ for robust, reproducible research outcomes.

• Signal Amplification in Translational Oncology: Strategic Ad

  2026-05-27

  Explore how mechanistic insights into caspase-8–driven cell death inform assay design, and how the Affinity-Purified Goat Anti-Rabbit IgG (H+L), Horseradish Peroxidase Conjugated Secondary Antibody empowers translational researchers to achieve robust, reproducible signal amplification in oncology workflows. This article uniquely bridges recent apoptosis and pyroptosis research with actionable guidance for next-generation immunoassays.

• Synergistic Inhibition of EMT in Pancreatic Cancer via CDK4/

  2026-05-26

  Gu et al. (2025) reveal that combining CDK4/6 and BET inhibitors produces a synergistic suppression of pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic advance identifies a promising therapeutic strategy to address the limitations of CDK4/6 monotherapy and offers guidance for future research on EMT and tumor progression.

• LY2886721: BACE Inhibitor Workflows for Alzheimer’s Research

  2026-05-26

  LY2886721 stands out as a potent, orally available BACE inhibitor enabling precise, tunable amyloid beta reduction in both in vitro and in vivo models. This guide unpacks evidence-backed protocols, troubleshooting strategies, and translational advantages for maximizing Alzheimer’s disease research outcomes with LY2886721.

• NF 340: A Selective P2Y11 Antagonist Empowering Cancer and I

  2026-05-25

  NF 340, a potent P2Y11 antagonist from APExBIO, is redefining experimental workflows in inflammation and cancer invasion studies. Its selectivity and robust GPCR signaling inhibition streamline assay design and enhance reproducibility for advanced immunology and cell migration models.

• TBK1 Inhibition Alleviates Diabetic Neuropathy via Microglia

  2026-05-25

  Liao et al. (2024) identify TANK-binding kinase 1 (TBK1) as a pivotal mediator of painful diabetic neuropathy (PDN) through its regulation of microglial pyroptosis in the spinal dorsal horn. Their findings demonstrate that genetic or pharmacological inhibition of TBK1, particularly with amlexanox, attenuates hyperalgesia and peripheral nerve injury in diabetic mouse models, offering a mechanistic target for future PDN therapies.

450 records 16/30 page Previous Next First page 上5页 1617181920 下5页 Last page